TABLE 4.
LFA performances per sample type for 0.5 and 1.0 cutoffs for diagnosing proven/probable CAPA versus possible/no CAPAa
| 0.5 ODI cutoff |
1.0 ODI cutoff |
|||
|---|---|---|---|---|
| Sensitivity (95% CI) | Specificity (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | |
| Respiratory samples | ||||
| Tracheal aspirate (TA) (NCAPA=16; NØCAPA=18) | 100% (79–100) | 44% (22–69) | 81% (54–96) | 67% (41–87) |
| Nondirected bronchial lavage (NBL) (NCAPA=4; NØCAPA=68) | 100% (40–100) | 66% (54–77) | 100% (40–100) | 74% (61–84) |
| Bronchoalveolar lavage fluid (BALF) (NCAPA=26; NØCAPA=64) | 77% (56–91) | 80% (68–89) | 58% (37–77) | 98% (92–100) |
| BALF and NBL combinedb (NCAPA=30; NØCAPA=132) | 80% (61–92) | 72% (63–79) | 63% (44–80) | 86% (78–91) |
| All combinedb (NCAPA=39; NØCAPA=146) | 85% (69–94) | 68% (60–76) | 67% (50–81) | 83% (76–89) |
| Serum samples (NCAPA=37; NØCAPA=111) | 22% (10–38) | 93% (86–97) | 11% (3–25) | 99% (95–100) |
a
For LFA performance for diagnosing proven/probable CAPA versus no CAPA (possible CAPA excluded) use sensitivity from Table 4 and specificity from Table 3. NCAPA, number of patients with proven/probable CAPA; NØCAPA, number of patients with possible CAPA or without CAPA.
b
For these lines, calculations were based on patients with any of the mentioned sample types. However, only 1 sample per patient was considered, with the following order of priority: BALF, NBL, TA.